Table 3 Comparison of clinical... | American Society of Hematology

Table 3

Comparison of clinical characteristics of cyclin D1⁻ and cyclin D1⁺ MCL patients from standard series published previously²²

Characteristic	Cyclin D1⁻	Cyclin D1⁺
n	40	71
Median age, y (range)	63 (33-90)	63 (38-92)
Sex, n (%)
Male	29 (73%)	53 (75%)
Female	11 (27%)	18 (25%)
Histology, n (%)
Classic	39 (97%)†	58 (82%)
Blastoid*	1 (3%)	13 (18%)
Ann Arbor stage, n (%)
I/II	4 (11%)	8 (11%)
III/IV	33 (89%)	62 (89%)
B-symptoms	5/19 (26%)	25 (35%)
High LDH	8/23 (35%)	26 (37%)
Extranodal involvement*	37/39 (95%)	53/68 (78%)
BM involvement	29/39 (74%)	39 (56%)
IPI score, n (%)
Low-risk (0,1)	3 (19%)	16 (26%)
Intermediate-risk (2,3)	11 (69%)	35 (56%)
High-risk (4,5)	2 (12%)	11 (18%)
Therapy, n (%)
Chemotherapy	10 (31%)	57 (83%)
Rituximab or immunochemotherapy*	19 (59%)	9 (13%)
Local therapy/no treatment	3 (10%)	3 (4%)
Response to therapy (CR + PR), n (%)	24/27 (88%)	53/66 (80%)
Median survival, mo	38	28

Characteristic	Cyclin D1⁻	Cyclin D1⁺
n	40	71
Median age, y (range)	63 (33-90)	63 (38-92)
Sex, n (%)
Male	29 (73%)	53 (75%)
Female	11 (27%)	18 (25%)
Histology, n (%)
Classic	39 (97%)†	58 (82%)
Blastoid*	1 (3%)	13 (18%)
Ann Arbor stage, n (%)
I/II	4 (11%)	8 (11%)
III/IV	33 (89%)	62 (89%)
B-symptoms	5/19 (26%)	25 (35%)
High LDH	8/23 (35%)	26 (37%)
Extranodal involvement*	37/39 (95%)	53/68 (78%)
BM involvement	29/39 (74%)	39 (56%)
IPI score, n (%)
Low-risk (0,1)	3 (19%)	16 (26%)
Intermediate-risk (2,3)	11 (69%)	35 (56%)
High-risk (4,5)	2 (12%)	11 (18%)
Therapy, n (%)
Chemotherapy	10 (31%)	57 (83%)
Rituximab or immunochemotherapy*	19 (59%)	9 (13%)
Local therapy/no treatment	3 (10%)	3 (4%)
Response to therapy (CR + PR), n (%)	24/27 (88%)	53/66 (80%)
Median survival, mo	38	28

CR indicates complete response; LDH, lactate dehydrogenase; NR, not reached; PR, partial response, y, years; and mo, months.

P < .05 by χ² test.

One case progressed from classical morphology to pleomorphic 4 years after diagnosis.